Molecular Pharmacology

Molecular Pharmacology (USA) Limited is a biotechnology company primarily focused on the development of novel analgesic and anti-inflammatory therapeutics. The company's core technology centers around MPL-TL (tripeptofen), a proprietary oligopeptide designed to target the pain and inflammation cascade through a mechanism distinct from traditional NSAIDs or opioids. Originally established as a mining venture named Blue Hawk Ventures, the entity pivoted to life sciences in 2005 following a merger and name change. While the company is publicly traded on the OTC Pink market under the symbol MLPH, it has recently been characterized as a shell company with limited operational activity. Its research efforts have historically targeted chronic pain and inflammatory conditions.